PLX

Protalix Biotherapeutics Inc

PLX.US protalix.com + Research + Basket
CIK 0001006281
Employees 226
Phone 201 696 9345
Fiscal year end December
IPO May 15, 1998
Address 2 University Plaza, Hackensack, NJ, United States, 07601
2.69
+0.08 (+3.07%)
USD · AMEX
52-week range
1.65
3.19
Trading at 68% of the 52-week range
Market Cap
210.29M
P/E Ratio
11.35
Forward P/E
51.28
Book Value
0.89
Div. Yield
N/A
% Institutions
24.20%
% Insiders
3.88%

1 Year

+15.0%

3 Year

+78.1%

10 Year

-39.0%
Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Actions

Add an action for PLX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Dror Bashan President, CEO & Director 1967
Mr. Gilad Mamlok Senior VP, CFO Treasurer & Secretary 1968
Mr. Yaron Naos B.Sc., MBA SVP & COO 1964
Ms. Yael Fellous Vice President of Human Resources NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 19, 2025 Dror Bashan N/A Purchase 56.00K $1.81 $101.36K SEC
Nov 18, 2025 Amos Bar-Shalev N/A Sale 168.00 $1.87 $314.16 SEC
Nov 18, 2025 Amos Bar-Shalev N/A Sale 168.00 $1.87 $314.16 SEC
Jun 10, 2025 Aharon Schwartz N/A Purchase 129.00K $1.60 $206.40K SEC

Financial Highlights

▼
Market Cap: $210.29M
EBITDA: $24.86M
P/E Ratio: $11.35
PEG Ratio: $-0.10
Book Value: $0.89
Earnings/Share: $0.23
Profit Margin: 23.50%
Operating Margin: 23.48%
ROA (TTM): 15.42%
ROE (TTM): 31.24%
Revenue (TTM): $80.62M
Revenue/Share (TTM): $1.01
Earnings Growth (YOY): 2,241.10%
Revenue Growth (YOY): 27.10%

Valuation Metrics

Enterprise Value: $174.81M
Trailing P/E: 11.35
Forward P/E: 51.28

Shares Statistics

Shares Outstanding: 80.57M
Shares Float: 77.45M
% Insiders: 3.88%
% Institutions: 24.20%
Shares Short: 3.51M
Shares Short (Prior Month): 2.88M
Short Ratio: 3.96
Short % Float: 4.53%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$52.74M
Cost of Goods Sold
adjust
$-27.51M
Gross Profit
subtotal
$25.24M
SG&A
adjust
$-11.68M
R&D
adjust
$-19.05M
Operating Income
subtotal
$-5.50M
Other / Non-Operating Items
adjust
$-1.10M
Net Income
subtotal
$-6.60M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PLX.US!